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Fructus mume extracts alleviate cognitive
impairments in 5XFAD transgenic mice
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Abstract
Background: Fructus mume (F. mume) has been used as a traditional treatment for ulcer, cough, and digestive
problems for many years in Asian countries. Previous studies have demonstrated that F. mume extracts alleviate
cognitive deficits in rats with chronic cerebral hypoperfusion and in mice with scopolamine treatments. The present
experiment was conducted to examine the effects of F. mume on cognitive impairments in 5XFAD transgenic mice
with five familial Alzheimer’s disease (AD) mutations.
Methods: F. mume was administered daily to 5XFAD mice at 12 weeks of age and continued for 90 days. Cognitive
function was evaluated using a spatial memory version of the Morris water maze task, the object/location novelty
recognition test, and contextual fear conditioning at 24 weeks of age. To elucidate the possible mechanisms
underlying the memory improving effects of F. mume in 5XFAD mice, we examined alterations in hippocampal
cholinergic function.
Results: Vehicle-treated 5XFAD mice exhibited hippocampus-dependent memory impairments compared with
non-transgenic littermates, which was reversed in F. mume-treated 5XFAD mice. In addition, reduced hippocampal
choline acetyltransferase (ChAT) levels in 5XFAD mice were reversed by F. mume treatment, indicating that F. mume
enhances the effects of cholinergic neuronal function.
Conclusions: F. mume may have therapeutic effects on cognitive impairments in AD.
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Background
Fructus mume (F. mume), the processed unripe fruit of
Prunus mume, has been used as a traditional treatment
for many years in Asian countries. F. mume has been re-
ported to be effective in a rat model of colitis induced by
2,4,6-trinitrobenzene sulfonic acid [1], and is inhibitory
to pro-inflammatory mediators in lipopolysaccharide
(LPS)-stimulated RAW 264.7 cells [2]. We recently re-
ported that F. mume treatment can alleviate impaired
cognitive function in a rat model of vascular dementia
(VaD) induced by a bilateral common carotid artery oc-
clusion (BCCAo) [3–6]. We also examined the effects of
F. mume on scopolamine-induced cognitive impairment
in mice [7]. In agreement with the results of the BCCAo
study, treatment with F. mume improved cognitive im-
pairments in scopolamine-injected mice [7].
These latter two studies [6, 7] also found that F. mume
has anti-inflammatory effects and enhances central cho-
linergic function. Based on this reported action of F.
mume, the present experiment was conducted to exam-
ine the therapeutic potential of F. mume for Alzheimer’s
disease (AD), using an animal AD model.
AD is characterized by a progressive loss of cognitive
function. The neuropathological hallmarks are the accu-
mulation of extracellular senile plaques and intraneuro-
nal fibrillary tangles, as well as the loss of basal forebrain
cholinergic neurons [8, 9]. In particular, numerous stud-
ies indicate that basal forebrain cholinergic neurons,
which provide the major innervation of the hippocam-
pus and cortex, play an important role in cognitive func-
tion [10–12]. The loss of basal forebrain cholinergic
neurons has been reported in the brains of patients with
VaD and AD. In addition, neurodegeneration of basal
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brains of BCCAo rats and AD transgenic mice [13–17].
Therefore, given that F. mume ameliorated BCCAo-
induced and scopolamine-induced cognitive impair-
ments, we expected beneficial effects of F. mume on
cognitive deficits in AD.
To investigate whether F. mume mitigates cognitive
impairments in AD, we used 5XFAD transgenic mice co-
overexpressing human amyloid precursor protein (APP)
and presenilin-1 (PS1) with five familial AD (FAD) muta-
tions. 5XFAD mice generate and accumulate cerebral
amyloid-β (Aβ) 42 and begin to develop visible amyloid
deposits at 2 months of age [18]. 5XFAD mice exhibit
memory decline, especially in hippocampus-dependent
behavioral tasks, at 4–6 months of age [19, 20]. In
addition, 5XFAD mice exhibit reduced choline acetyl-
transferase (ChAT) levels in the hippocampus and loss of
cholinergic neurons in the medial septum (MS) and the
vertical limb of diagonal band (VDB) at 6 months of age
[21]. In the present study, 5XFAD mice were administered
F. mume for approximately 3 months and then followed
several behavioral tasks for assessing cognitive function.
F. mume treatment alleviated cognitive impairments via
increases in hippocampal ChAT levels.
Methods
Preparation of F. mume extracts
F. mume was purchased from a commercial supplier
(Kwangmyung-Dang, Ulsan, Korea) in 2010. It was iden-
tified by the Herbal Quality Control Team and deposited
at the Creative Research Laboratory, KIOM (Korea).
Dried F. mume was pulverized and extracted with dis-
tilled water (2 kg/8 L) for 2 h below 100 °C in an
ultrasound-assisted extractor (OM30-EP; Sonimedi,
Korea). All extracts were concentrated under vacuum
using a rotary evaporator after filtration and were then
dried for 48 h at 40 °C by using an extract vacuum drier
(Exdryer, Sonimedi, Korea) to yield a powder extract
(324.5 g, 16.225 % yield). The powder extract was sus-
pended in sterilized distilled water at the appropriate
concentrations. An HPLC assay was performed with cit-
ric acid as a standard maker for quality control of the F.
mume extract composition in each experiment. HPLC
was performed using two Waters 515 pumps, a 2996
photodiode array detector, and a Phenomenex Synergi
Hydro RP-80A (4 m, 4.6 x 250 mm i.d.). The mobile
phase was composed of acetonitrile (A) and 0.1 % phos-
phoric acid (B) with a linear gradient elution: 0 min,
100 % B; 15 min, 3.8 % A. F. mume extract was filtered
on membrane filters with a 0.45 mm pore size (Milli-
pore) and a 10 L injection volume. Citric acid was de-
tected at a wavelength of 220 nm. The crude extract was
analyzed in triplicate, and the citric acid content was
found to be about 18.68 % [6, 22].Animals and F. mume extract administration
The generation of 5XFAD mice (Tg6799 line) has been
described previously [18]. These mice co-express and
co-inherit both mutant human APP (695) with the
Swedish (K670N, M671L), Florida (I716V), and London
(V717I; FAD) mutations and human PS1 harboring two
FAD mutations, M146L and L286V. The expression of
these transgenes is regulated by neuron-specific mouse
Thy-1 promoters to drive overexpression in the neurons.
The 5XFAD strain (B6/SJL genetic background) was
maintained by crossing hemizygous transgenic mice with
non-transgenic B6/SJL breeders, and 5XFAD transgenic
mice were used for the experiments with non-transgenic
littermates as controls. Before the experiments, genomic
DNA was extracted from the tail tips of all mice and
genotyping was performed by polymerase chain reaction
analysis. 23 non-transgenic controls (18 male, 5 female)
and 38 5XFAD (28 male, 10 female) mice were used for
the experiments. All mice had access to food and water
ad libitum and were housed under a 12–12 h light–dark
cycle at 22–24 °C. All behavioral experiments were per-
formed during the light phase.
Preparation of F. mume has been described previously
[6]. Mice were administered F. mume extract (200 mg/
kg) or distilled water as a vehicle control by oral gavage.
Treatment began when the mice were 12 weeks of age
and continued until they were sacrificed, for approxi-
mately 3 months. The Institutional Animal Care and
Use Committee of Konkuk University approved all pro-
tocols described in this report.
Morris water maze task
The Morris water maze test pool was 1.83 m in diam-
eter, and 0.58 m in height, with a 0.2 m in diameter hid-
den platform and was surrounded by a white curtain
marked with extra-visual cues. The pool was filled with
24–27 °C opaque water. Mice were trained on four trials
per day for 8 consecutive days. Mice were allowed to
search for the platform for 60 s; if they did not find the
platform, they were placed on the platform manually,
where they were held for 15 s. After the trials were com-
pleted, the mice were dried and placed back into their
home cages. To assess memory retention, a probe test
was performed on training day 5, 7, and 9. During the
probe test, platform was removed and mice were allowed
to swim for 30 s. In all trials, the movements of the mice
were recorded and analyzed using a HVS image tracking
system (Hampton, UK).
Contextual fear conditioning task
Contextual fear conditioning task was conducted in
square (18 cm W x 18 cm D x 30 cm H) chambers
equipped with a steel-grid floor through which foot-
shock could be delivered (Coulbourn, PA, USA). The
Park et al. BMC Complementary and Alternative Medicine  (2016) 16:54 Page 3 of 8task consisted of habituation, training, and test sessions.
During habituation, the mice were placed in a condition-
ing chamber and allowed to explore without a foot
shock for 12 min. On the next day, during training, mice
were placed in the conditioning chamber for 148 s, and
then received three unsignaled foot shocks (0.75 mA,
2 s) at 30-s intervals. The test session was scheduled
24 h after training. During the test, mice were placed
into the same conditioning chamber, and contextual fear
memory was evaluated by scoring freezing behavior for
3 min by an investigator blind to condition. In addition,
the baseline freezing behavior was analyzed during the
2 min before the delivery of the foot shock during the
training session.
Object/location novelty recognition test
The object/location novelty recognition test consisted of
four sessions: habituation, sample object phase, novel
object phase, and novel object location phase. Each
mouse was individually habituated to the open field box
(50 × 50 cm) for 15 min. On the next day during the
sample object phase, two identical sample objects were
placed in the two corners of the box, and the mice were
allowed to freely explore the arena and objects for
10 min. The novel object phase was scheduled 24 h later,
in which the mice were placed into the arena again, and
one of the sample objects was replaced with a novel ob-
ject. Mice were allowed to explore the arena for 5 min,
and the time spent exploring each object was scored for
2 min. 24 h later, during the novel object location
phase, one of the two objects that were used in novel
object phase was moved to a novel place in the arena,
and the mice were tested in the same way as before.
The discrimination ratio was calculated as the ratio of
time spent exploring the novel object or the object
moved to novel location to the total time spent explor-
ing the two objects.
Western blot analysis
One week after the behavioral experiments, 9 mice per
group were decapitated and the hippocampal or cortical
samples were dissected and snap-frozen. For the total
protein extracts, individual tissue samples were homoge-
nized in ice-cold buffer containing 20 mM Tris (pH 7.5),
5 % glycerol, 1.5 mM EDTA, 40 mM KCl, 0.5 mM di-
thiothreitol, and protease inhibitors. The homogenates
were then centrifuged at 14,000 rpm for 1 h at 4 °C, and
the supernatant was harvested and stored at−80 °C. The
concentration of the protein extracts was determined by
the Bradford assay. The protein extracts were separated
by SDS-PAGE and transferred to a PVDF membrane
using the Mini Trans-Blot Cell (Bio-Rad). After block-
ing, the membranes were incubated with anti-ChAT
antibody (goat polyclonal; millipore, 1:1000), anti-β-actinantibody (sigma, 1:5000), and then with HRP-conjugated
secondary antibodies. The signals were visualized by an
ECL system and developed onto hyperfilm. The relative
ChAT expression level was determined by densitometry
using the Image Gauge software (Fujifilm) and was nor-
malized to β-actin levels.Immunohistochemistry
One week after the behavioral experiments, 6 mice per
group were euthanized by ketamine and xylazine and
were intracardially perfused with 4 % paraformaldehyde
(PFA) in phosphate buffered saline (PBS). Following fix-
ation, the brains were removed to 4 % PFA and 30 % su-
crose solutions, respectively, in order. Free-floating brain
sections (40 μm) were obtained from frozen-section
mice brains using microtome (Leica). Endogenous per-
oxidase activity in the brain sections was quenched by
incubation in 3 % H2O2/10 % MeOH in PBS. The sec-
tions were then incubated for 1 h at room temperature
in PBS with 0.3 % Triton-X 100 containing 10 % fetal
horse serum (GIBCO). The sections were incubated with
anti-ChAT antibody (goat polyclonal; Millipore, 1:1000)
overnight and then incubated for 1 h with the appropri-
ate biotinylated secondary antibodies (Vector, 1:500) and
for 2 h in extravidin peroxidase conjugate (Sigma Aldrich,
1:1000). Finally, the sections were reacted with a 3,3′-di-
aminobenzidine (DAB) substrate kit (Vector) and
mounted onto resin coated slides. After dehydration in a
series of ethanol and clearance in xylene, the slides were
covered with a coverslip using permount reagent. To
quantify the number of ChAT-positive cells, 8 sec-
tions from the medial septum region (between +1.2
and +0.8 mm anterior to the bregma) and 4 sections
from the substantia innominata region (between +0.3
and +0.1 mm anterior to the bregma) were selected
from each individual. To capture the images, light mi-
croscopy was conducted on ECLIPSE Ni-U micro-
scope (Nikon, Japan) equipped with a ProgRes CFscan
camera (JENOPTIK, Germany). After the same threshold
level and region of interest were applied to each image,
the number of ChAT-positive cells was counted using
MetaVue software.Statistical analysis
One-way analysis of variance (ANOVA) or two-way
ANOVA with repeated measurements was conducted to
assess the effects of the F. mume extract on the changes
in hippocampal and cortical ChAT levels and the cogni-
tive impairments in 5XFAD mice. Post-hoc analyses
(Least Significant Difference test) were subsequently per-
formed to determine the effects of the F. mume treat-
ment. P values of less than 0.05 were considered
significant, unless otherwise specified. The data were
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Results
F. mume alleviated cognitive impairments in 5XFAD mice
To examine the effect of F. mume on cognitive impair-
ments in 5XFAD mice, several hippocampus-dependent
behavioral tasks were conducted (Fig. 1). We first con-
ducted the Morris water maze task to assess spatial
memory. It has previously been reported that 5XFAD
mice exhibit memory impairment in the Morris water
maze task at 6 months of age [23]. In the present experi-
ment, all mice improved in locating the submerged plat-
form across the 8 training sessions, as shown by
decreasing latency (Fig. 2a; two-way ANOVA with 4 tri-
als/session as a repeated measure; main effect of train-
ing: F(7,203) = 20.01, p < 0.001). Neither the main effect of
treatment (F(2,29) = 1.97, p = 0.16) nor the interaction ef-
fects of treatment x training (F(14,203) = 1.51, p = 0.11)
were significant. Post-hoc analyses revealed that per-
formance of 5XFAD mice was poorer than those of
vehicle-treated control at the session 4 (p < 0.05) and
that performance of F. mume-treated 5XFAD mice was
improved compared with vehicle-treated 5XFAD mice at
the session 4 and 5 (p < 0.05) (Fig. 2a). However, no sig-
nificant difference between the groups was found during
the probe trials for the assessment of spatial memory re-
tention (Fig. 2b).
Mice were then tested on object recognition task and
the location novelty recognition task. Briefly, mice were
initially exposed to two identical objects and re-exposed
to the objects 24 h later when one of the objects was re-
placed with a novel object. After this novel object phase,
the mice were tested again in a location novelty recogni-
tion test in which one of the objects was moved to a
novel location in the arena. The location novelty recog-
nition task is known to be sensitive to hippocampal
damage [24]. In the novel object phase, no significantFig. 1 Experimental procedure. Daily treatment with F. mume (200 mg/kg)
Behavioral experiments including the Morris water maze, the object/locatio
sequentially conducted at 24 weeks of agedifference in the discrimination ratio was observed be-
tween the groups. However, in the new location phase, a
difference in the discrimination ratio between groups
was found. One-way ANOVA revealed significant
between-group effects (F(2, 46) = 4.360, p < 0.05). Post-hoc
analyses revealed that vehicle-treated 5XFAD mice spent
less time exploring the object moved to novel location
compared with the vehicle-treated control mice (Fig. 3a)
and that the discrimination ratio in F. mume-treated
5XFAD mice was increased relative to vehicle-treated
5XFAD mice (p < 0.05) (Fig. 3a).
The final task was contextual fear conditioning, in
which mice learned an association between a context
(a conditioning chamber) and an aversive stimulus (a
foot shock). An earlier study reported that fear mem-
ory was impaired in 5XFAD mice [19]. We measured
basal levels of freezing behavior in the conditioning
chamber before the foot shock delivery. Even though
the basal levels of freezing behavior were low in all
the groups, one-way ANOVA revealed significant
between-group effects (F(2, 46) = 3.08, p < 0.05). Specif-
ically, vehicle-treated 5XFAD mice exhibited slightly
more freezing behavior than vehicle-treated non-
transgenic mice. In contrast, the basal levels of freez-
ing behavior were decreased in F. mume-treated
5XFAD mice compared with vehicle-treated 5XFAD
mice. During the test session conducted 24 h after re-
ceiving the foot shock, the freezing levels were in-
creased in all the groups, but with significant
between-group differences (F(2, 45) = 7.84, p < 0.01).
Post-hoc analyses revealed that vehicle-treated 5XFAD
mice exhibited reduced freezing behavior compared
with vehicle-treated non-transgenic mice (p < 0.05),
which implies that the fear memory was impaired in
5XFAD mice. This fear memory impairment was res-
cued by F. mume treatment (p < 0.05) (Fig. 3b). To-
gether these results suggest that F. mume is effective
in improving cognitive dysfunction in 5XFAD mice.or vehicle was initiated at 12 weeks of age and continued for 90 days.
n novelty recognition test, and contextual fear conditioning were
Fig. 2 Treatment with F. mume ameliorated impairments in spatial learning on the Morris water maze in 5XFAD mice. a During the hidden
platform training sessions, vehicle-treated 5XFAD mice exhibited a significant learning deficit during the spatial learning training compared with
vehicle-treated non-transgenic mice (*p < 0.05). F. mume treatment alleviated this impairment in spatial learning (#p < 0.05 versus vehicle-treated
5XFAD mice) on sessions 4 and 5. b Probe trials were conducted before the acquisition trials on sessions 5, 7, and 9 to assess the retention of
spatial memory. The percentage of time spent in the target quadrant was analyzed over 30 s. No significant differences were observed between
the groups (n = 8 – 14 per group). All the data are presented as the mean ± SEM
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expression in the hippocampus of 5XFAD mice
It has been reported that the septo-hippocampal cholin-
ergic system is impaired in 5XFAD mice [21, 25]. To
elucidate the possible mechanisms contributing to the
memory improving effect of F. mume, hippocampal and
cortical ChAT expression levels were measured by west-
ern blot analysis (Fig. 4a). One-way ANOVA revealed
significant between-group effects on the hippocampal
ChAT levels (F(2, 15) = 16.435, p < 0.01) (Fig. 4a and b).
Post-hoc analyses revealed that hippocampal ChAT
levels was significantly reduced in vehicle-treatedFig. 3 F. mume treatment ameliorated impairments in recognition and fea
test consisted of a novel object and novel location phase. During the obje
were observed between the groups, whereas, during the subsequent nove
for the object moved to the novel location than vehicle-treated non-transgen
b During contextual fear conditioning, mice were exposed to a context (cond
shocks (0.75 mA, 2 s, 30 s interval). Context-associated fear memory was meas
vehicle-treated 5XFAD mice exhibited less freezing behavior than vehicle-trea
F. mume (#p < 0.05). During the baseline, prior to the foot shock delivery, vehi
groups (*,#p < 0.05) (n = 16 – 17 per group). All the data are presented as the5XFAD mice compared with vehicle-treated non-
transgenic mice, which was reversed by F. mume treat-
ment (p < 0.05) (Fig. 4a and b). No significant between-
group differences were observed in cortical ChAT
expression levels (Fig. 4a and c).
To further examine the status of cholinergic neurons
in the basal forebrain of these mice, the number of
ChAT-positive neurons in the medial septum (MS) and
the vertical limb of the diagonal band (VBD), which
provide the main cholinergic innervation to the hippo-
campus, were counted using immunohistochemistry
(Fig. 4d). Consistent with previous studies [19], ther memory in 5XFAD mice. a The object/location novelty recognition
ct phase, no significant differences in the preference for a novel object
l location phase, vehicle-treated 5XFAD mice exhibited less preference
ic mice (*p < 0.05), which was reversed by F. mume treatment (#p < 0.05).
itioning chamber) for 148 s and then received three unsignaled foot
ured by observing freezing behavior 24 h later. During the test phase,
ted non-transgenic mice (*p < 0.05), which was reversed by treatment of
cle-treated 5XFAD mice exhibited more activity than mice in the other
mean ± SEM
Fig. 4 F. mume treatment increased hippocampal ChAT expression in 5XFAD mice. a Hippocampal or cortical ChAT expression level was analyzed
by western blot (normalized to non-transgenic + vehicle). b The expression levels of hippocampal ChAT were significantly reduced in vehicle-
treated 5XFAD mice compared with vehicle-treated non-transgenic mice (*p < 0.05). F. mume treatment mitigated this reduction (#p < 0.05) (n = 6
per group). c No significant differences in expression levels of cortical ChAT were found between the groups (n = 8 – 9 per group). d Representative
ChAT-positive neurons in the medial septum (MS) and substantia innominata (SI) are shown. Scale bar = 100 μm. e The number of ChAT-positive
neurons in the MS and vertical limb of the diagonal band (VDB), which provide cholinergic innervation to the hippocampus, was counted (n = 6 per
group). f The number of ChAT-positive neurons in the SI and horizontal limb of the diagonal band (HDB), which provide cholinergic innervation to the
cortex, was counted (n = 4 per group). No significant differences were observed in the number of ChAT-positive neurons in the basal forebrain
between the groups. All the data are presented as the mean ± SEM
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vehicle-treated 5XFAD mice and F. mume-treated
5XFAD mice (Fig. 4d and e). Furthermore, the number
of ChAT-positive neurons that project to the cortex
within the horizontal limb of the diagonal band (HDB),
the magnocellular preoptic nucleus (MCPO), and the
substantia innominata (SI) was not significantly differ-
ent between groups (Fig. 4d and f ). These results indi-
cate that F. mume ameliorates impaired cholinergic
function via the up-regulation of hippocampal ChAT
levels rather than by prevention of cholinergic neurode-
generation in 5XFAD mice.
Discussion
F. mume, the smoked fruit of Prunus mume SIEB. et
Zucc. (Rosaceae family), has been used to treat gastro-
intestinal disease, ulcer, and cough in Asian countries
for thousands of years [1]. The therapeutic effects and
mechanisms F. mume extract on macrophage-mediated
inflammation were examined in LPS-stimulated RAW
264.7 cells. F. mume treatment inhibited the LPS-
induced production of nitric oxide, prostaglandin E2,
and interleukin-6 production. F. mume treatment also
suppressed the signaling of mitogen-activated protein
kinase and nuclear factor-κB activated by LPSstimulation [2]. In addition, F. mume extract was an ef-
fective treatment in an animal model of colitis [1].
Based on the results reported above, additional studies
were conducted to examine the effects of F. mume ex-
tract on chronic BCCAo-induced microglial activation
and the resultant cognitive improvement. F. mume-
treated BCCAo rats exhibited less inflammation and
more improvements in spatial memory compared with
vehicle-treated BCCAo rats [6, 26]. However, it is pos-
sible that F. mume attenuates basal forebrain cholinergic
neurons impairments in rats with chronic BCCAo based
on the observation of neurodegeneration in the basal
forebrain cholinergic neurons of rats with chronic
BCCAo [13] as well as observation that F. mume res-
cued scopolamine-induced spatial memory and choliner-
gic system impairments [7].
Hippocampal ChAT levels are markedly reduced in
the brains of AD patients [27]. Studies have demon-
strated that treatments leading to the up-regulation of
hippocampal acetylcholine (ACh) levels reverse memory
deficits [28]. For example, cognitive deficits induced by
fimbria-fornix lesions are attenuated by ACh-secreting
fibroblasts implanted into the hippocampus [12]. Simi-
larly, hippocampal grafts of fetal neuronal tissue rich in
cholinergic neurons reverse memory deficits produced
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campal, fimbria-fornix lesions, and selective 192 IgG-
saporin-induced lesions of the septo-hippocampal ACh
projection [29–31].
In addition, the expression level of acetylcholinesterase
(AChE), which breaks down ACh, has been examined
in relation to AD pathology. Indeed, an Aβ-induced
AChE increase has been observed both vitro and
in vivo [32–34]. There was a positive correlation be-
tween the Aβ level and AChE activity in human cere-
brospinal fluid [35]. AChE may interact with Aβ to
accelerate the deposition of amyloid plaque in the
brains of AD patients [36]. To counteract this detri-
mental action of AChE in AD, AChE inhibitors such as
donepezil are widely used. The therapeutic effect of
AChE inhibitors has also confirmed in a mouse model
of AD [37].
Therefore, the present study examined the efficacy of
F. mume on cognitive deficits in AD using 5XFAD
transgenic mice. Specifically, cognitive status was mea-
sured in vehicle-treated non-transgenic, vehicle-treated
5XFAD, and F. mume-treated 5XFAD mice using the
Morris water maze, location novelty recognition, and
contextual fear conditioning tasks. Impairments in the
spatial version of the Morris water maze task, location
novelty recognition task, and contextual fear condition-
ing task were observed in vehicle-treated 5XFAD mice
relative to vehicle-treated non-transgenic mice, which
is consistent with earlier reports [20, 38]. These cogni-
tive impairments were alleviated in the F. mume-treated
5XFAD mice.
Moreover, we measured hippocampal and cortical
ChAT levels using western blot analysis and counted the
number of cholinergic neurons in the basal forebrain
using immunohistology in the vehicle-treated non-
transgenic, vehicle-treated 5XFAD, and F. mume-treated
5XFAD mice, to reveal the underlying action mechanism
of F. mume. A significant difference in the number of
ChAT-positive neurons in the MS and the VBD, which
innervate to the hippocampus, and the hippocampal
ChAT levels was observed between vehicle-treated non-
transgenic and vehicle-treated 5XFAD mice, in agree-
ment with previous reports [21, 25]. Hippocampal ChAT
levels were restored in the F. mume-treated 5XFAD
mice. However, no statistical difference between vehicle-
treated non-transgenic and vehicle-treated 5XFAD mice
was observed in the number of cortically projecting
ChAT-positive neurons in the HDB, MCPO, and SI.
F. mume-treatment is reported to increase ChAT
levels and decrease AChE levels in the hippocampus [7].
A study that explores AChE levels in the hippocampus
and cortex of F. mume-treated 5XFAD mice is needed to
support the hypothesis that F. mume acts on cholinergic
neurons. In addition to improving cholinergic function,the anti-inflammatory effects of F. mume have been re-
ported in a rat model of VaD using chronic cerebral hy-
poperfusion [6]. In that study, the expression levels of
neuroinflammation markers such as activated microglia
cells were reduced by F. mume. However, several stud-
ies from those in transgenic mice (including 5XFAD
mice) to those in AD patients have demonstrated the
crucial roles of neuroinflammation in AD pathology
[18, 39, 40]. Thus, it is worth noting that the anti-
inflammatory effect of F. mume may also contribute to
cognitive deficit improvements.
Conclusion
The present study demonstrated that F. mume improved
cognitive impairments in 5XFAD mice. These results are
consistent with previous reports in a chronic cerebral
hypoperfusion rat model of VaD and in a scopolamine-
induced model of memory impairment in mouse. F.
mume also increased hippocampal ChAT expression
levels, which provides evidence that F. mume has a
therapeutic effect on impaired cholinergic functions in
AD pathology. Therefore, these results suggest that F.
mume may be a novel agent for the cognitive improve-
ment and the restoration of cholinergic systems in AD.
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